# AbbVie Inc. (ABBV) FY2024 YTD Q3 P&L / Income Statement

- Company: AbbVie Inc. (ABBV)
- Period: 2024-01-01 to 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-11-04, accession number 0001551152-24-000040
- Page: https://plicit.ai/financials/abbv/fy2024-ytd-q3-income-statement
- Chart image: https://plicit.ai/charts/abbv-fy2024-ytd-q3-income-statement-sankey.png

## Chart details: Revenue by Key Product Portfolio by Product and Service

Income statement for 2024-01-01 through 2024-09-30. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenues**: 41,232,000,000 US dollars
- **Cost of products sold**: 12,508,000,000 US dollars
- **Gross profit (calculated)**: 28,724,000,000 US dollars
- **Operating expenses (calculated)**: 18,097,000,000 US dollars
- **Operating earnings**: 10,627,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 4,642,000,000 US dollars
- **Earnings before income tax expense**: 5,985,000,000 US dollars
- **Income tax expense**: 1,676,000,000 US dollars
- **Net earnings**: 4,309,000,000 US dollars
- **Aesthetics - Botox Cosmetic**: 2,033,000,000 US dollars
- **Aesthetics - Juvederm Collection**: 898,000,000 US dollars
- **Aesthetics - Other Aesthetics**: 947,000,000 US dollars
- **Eye Care - Alphagan/Combigan**: 170,000,000 US dollars
- **Eye Care - Lumigan/Ganfort**: 310,000,000 US dollars
- **Eye Care - Other Eye Care**: 632,000,000 US dollars
- **Eye Care - Ozurdex**: 374,000,000 US dollars
- **Eye Care - Restasis**: 110,000,000 US dollars
- **Hematologic Oncology - Epkinly**: 106,000,000 US dollars
- **Hematologic Oncology - Imbruvica**: 2,499,000,000 US dollars
- **Hematologic Oncology - Venclexta**: 1,928,000,000 US dollars
- **Immunology - Humira**: 7,311,000,000 US dollars
- **Immunology - Rinvoq**: 4,137,000,000 US dollars
- **Immunology - Skyrizi**: 7,940,000,000 US dollars
- **Neuroscience - Botox Therapeutic**: 2,410,000,000 US dollars
- **Neuroscience - Duodopa**: 339,000,000 US dollars
- **Neuroscience - Other Neuroscience**: 238,000,000 US dollars
- **Neuroscience - Qulipta**: 457,000,000 US dollars
- **Neuroscience - Ubrelvy**: 703,000,000 US dollars
- **Neuroscience - Vraylar**: 2,343,000,000 US dollars
- **Other Key Products - Linzess/Constella**: 721,000,000 US dollars
- **Other Key Products - Mavyret**: 1,020,000,000 US dollars
- **Undisclosed (calculated)**: 3,606,000,000 US dollars
- **Acquired IPR&D and milestones**: 1,183,000,000 US dollars
- **Research and development**: 6,017,000,000 US dollars
- **Selling, general and administrative**: 10,897,000,000 US dollars
- **Other operating income**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to AbbVie Inc.: $4.30 B; to noncontrolling interests: $9.00 M.